Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2006-05-23
2006-05-23
Smith, Lynette R. F. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C424S247100
Reexamination Certificate
active
07048927
ABSTRACT:
The present invention provides for methods of treating cardiovascular diseases in a mammal. The methods include a step of administering an effective amount of a botulinum toxin directly to a blood vessel of a mammal thereby treating a cardiovascular disease.
REFERENCES:
patent: 5092841 (1992-03-01), Spears
patent: 5385935 (1995-01-01), Tamai et al.
patent: 5437291 (1995-08-01), Pasricha et al.
patent: 5562907 (1996-10-01), Arnon
patent: 5766605 (1998-06-01), Sanders et al.
patent: 5851786 (1998-12-01), Johnson
patent: 5865794 (1999-02-01), Castro
patent: 5939070 (1999-08-01), Johnson et al.
patent: 5989280 (1999-11-01), Euteneuer et al.
patent: 6063768 (2000-05-01), First
patent: 6102904 (2000-08-01), Vigil et al.
patent: 6121296 (2000-09-01), Schramm et al.
patent: 6183506 (2001-02-01), Penn et al.
patent: 6190404 (2001-02-01), Palmaz et al.
patent: 6196230 (2001-03-01), Hall et al.
patent: 6217608 (2001-04-01), Penn et al.
patent: 6238872 (2001-05-01), Mosseri
patent: 6239118 (2001-05-01), Schatz et al.
patent: 6241758 (2001-06-01), Cox
patent: 6261318 (2001-07-01), Lee et al.
patent: 6264671 (2001-07-01), Stack et al.
patent: 6270521 (2001-08-01), Fischell et al.
patent: 6290961 (2001-09-01), Aoki et al.
patent: 6293959 (2001-09-01), Miller et al.
patent: 6299893 (2001-10-01), Schwartz et al.
patent: 6306162 (2001-10-01), Patel
patent: 6306423 (2001-10-01), Donovan et al.
patent: 6312708 (2001-11-01), Donovan
patent: 6319505 (2001-11-01), Aoki et al.
patent: 6344055 (2002-02-01), Shukov
patent: 6383509 (2002-05-01), Donovan et al.
patent: 6429189 (2002-08-01), Borodic
patent: 6464986 (2002-10-01), Aoki et al.
patent: 6579847 (2003-06-01), Unger
patent: 6767544 (2004-07-01), Brooks et al.
patent: 2003/0185860 (2003-10-01), Brooks
patent: WO 00/04922 (2000-02-01), None
patent: 01/10458 (2001-02-01), None
patent: WO 01/10458 (2001-02-01), None
patent: WO 01/21213 (2001-03-01), None
patent: 01/82947 (2001-11-01), None
patent: WO 02/053181 (2002-07-01), None
Mukherjee et al, Expandable Metal Stents in Achalasia- Is There a Role?, Nov. 9, 2000, Elsevier Science Inc., vol. 95, 2185-2187.
Rappuoli et al., Guidebook to Protein Toxins and Their Use in Cell Biology, 1997, Oxford University Press, pp. 66 and 108.
Muniyappa, R. et al., Am. J. Physiol. Heart Cir. Physiol., vol. 278, (6) pp. H1762-H1768, Jun. 2000.
Johnson, Eric. Clostridial toxins as therepeutic agents: benefits of nature's most toxic proteins. Annu Rev Microbiol 53: 551-575, 1999.
Schmitt et al. Bacterial toxins: friends or foes? Emerg Infect Dis 5(2): 224-234, 1999.
Muniyappa, R et al, Am. J. Physiol. Heart Cir. Physiol., vol. 278, (6) pp. H1762-H1768, Jun. 2000.
DePalma, GD et al, Endoscopy, Dec. 2001, vol. 33(12), pp. 1027-1030.
Maria, G et al, Diseases of the colon & Rectum, 2000, vol. 43(5), May, pp. 721-723.
Tan, EK et al, Movement disorders, vol. 14(2), pp. 345-349, 1999.
Tsuboi et al. Botulinum neurotoxin A blocks cholinergic ganglionic neurotransmission in the dog heart. Jpn J Pharmacol 89(3): 249-254, 2002.
Tsuboi et al. Inotropic, chronotropic, and dromotropic effects mediated via parasympathetic ganglia in the dog heart. Am J Physiol Heart Circ Physiol 279: H1201-H1207, 2000.
Mangrum et al. The evaluation and management of bradycardia. N Eng J Med 342(10): 703-709, 2000.
Aktories, K., et al.,Clostridium botulinum C3 ADP-Ribosyltransferase, Current Topics in Microbiology and Immunology, vol. 175, 1992, 115-131.
Fauci, A.S., et al.,14thEdition Harrison's Principles of Internal Medicine, McGraw-Hillpp 904-907, 1998.
Fiorentini, C. et al.,Bacterial toxins and the Rho GTP-binding protein: what microbes teach us about cell regulation, Cell Death and Differentiation (1998) 5, pp. 720-728.
Nishiki, T., et al.,Morphological effects of clostridium botulinum C3 exoenzyme on cultured cells, Jpn. J. Med. Sci. Biol. 43, 1990, 261-262.
U.S. Appl. No. 09/678,189, filed Oct. 4, 2000, Brooks et al.
U.S. Appl. No. 09/620,840, filed Jul. 21, 2000, Steward et al.
U.S. Appl. No. 09/489,667, filed Jan. 19, 2000, Donovan.
U.S. Appl. No. 09/922,093, filed Aug. 3, 2001, Donovan.
U.S. Appl. No. 09/625,098, filed Jul. 25, 2000, Donovan.
U.S. Appl. No. 09/910,346, filed Jul. 20, 2001, Steward.
Claus, D., et al., Botulinum Toxin: influence on respiratory heart rate variation, Mov Disord 1995 Sep.; 10(5): 574-579.
Girlanda, P., et al., Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system, J. Neurol Neurosurg Psychiatry 1992;55(9):844-5.
Lamanna, C., et al., Cardiac Effects of Botulinal Toxin, Arch Int Pharmacodyn Ther 1988; 293: 69-83.
Malnick, S., et al., Fatal heart block following treatment with botulinum toxin for achalasia, Am J Gastroenterol 2000;Nov.; 95(11):3333-3334.
Nebe, A., et al., No effects on heart-rate variability and cardiovascular reflex tests after boulinum toxin treatment of cervical dystonia, Mov Disord May, 1996; 11(3):337-339.
Sathyamoorthy, V., et al., Separation, purification, particial characterization and comparison of the heavy and light chains of botulinum neurotoxin types A, B and E, The J. of Biol. Chem, vol. 260, No. 19, Sep. 5, pp. 10461-10466, 1985.
Shone, C., et al., A 50-kDa fragment from the NH2-terminus of the heavy subunit of clostridium botulinum type A neurotoxin forms channels in lipid vesicles, Eur. J, Biochem 167, 175-180, 1987.
Author Unknown, Internet, Drug-coated stents help eliminate angioplasty problems, Mar. 18, 2002, www.cnn.com/2002/helath/03/18/heart.angioplasty.ap/index.html. 3 pgs.
Ayers, G.M., et al.;Amiodarone Instilled Into the Canine Pericardial Sac Migrates Transmurally to Produce Electrophysiologic Effects and Suppress Atrial Fibrillation; Journal of Cardiovascular Electrophysiology; vol. 7, No. 8; Aug. 1996; 713-721.
Lamanna, C., et al.;Cardiac Effects of Botulinal Toxin; Arc. Int. Pharmacodyn.; 1988; vol. 293; 69-83.
Lamanna, C.;Thoughts on Action of Botulinum Toxin Suggested by Reversibility of Heart Effects; Botulinum and Tetanus Neurotoxins(edited by Dasgupta, B.R.); 1993 Plenum Press; 333-335.
McDermott, D.A., et al.;Use of an Indwelling Catheter for Examining Cardiovascular Responses to Pericardial Administration of Bradykinin in Rat; Cardiovascular Research; 1995; vol. 30; 39-46.
Galardi et al.: “The Local Injection of Botulinum Toxin Can Effect the Neural Control of Heart Rate Variability.”, Nerology, vol. 44, 1994, pp. A307-A308.
Kimura et al.; “Negative Chronotropic Effect of Botulinum Toxin on Neonatal Rat Cardiac Mycocytes.” Biochem. Biophys. Res. Comm., vol. 244, 1998, pp. 275-279.
Dickson, E.,Studies on the Manner in which the Toxin of Clostridium Botulinum Acts Upon the Body, J. Exper Med 37: 711-31 (1923) d.
Fauci, A.,Harrison's Principles of Internal Medicinefourteenth edition (1997), McGraw Hill.
Nattel, S.,Comparative Mechanisms of Action of Antiarrhythmic Drugs, Am J. Cardiol, 72: 13F-17F (1993).
Wit, A.,Electrophysiological Basis for Antiarrhythmic Drug Action, Clin. Physiol. Biochem. 3: 127-134 (1985).
Waxman, S.,Persistent Primary Coronary Dilation Induced by Transatrial Delivery of Nitroglycerin into the Pericardial Space: A Novel Approach for Local Cardiac Drug Delivery, J Am Coll Cardiol 33: (7); 2073-2077 (1999).
Claus, D.,Botulinum Toxin: Influence on Respiratory Heart rate Variation, Mov Disord 10(5): 574-9 (1995).
Kimura, K.,Negative Chronotropic Effect of Botulinum Toxin on Neonatal Rat Cardiac Myocytes, Biochem Biophys Res Commun 6; 244 91):275-9 (1998).
Nebe, A.,No Effects on Heart-Rate Variability and Cardiovascular Reflex Tests After Botulinum Toxin Treatment of Cervical Dystonia, Mov Disord; 11 (3): 337-9 (1996).
Glaradi, G.,The Local Injection of Botulinum Toxin can Affect the Neural Control of Heart Rate Variability, Neural 44; (Sup 2): A307-A308 (1994).
Laham, R.,Therapeutic Myocardial Angiogenesis Using Percutaneous Intrapericardial Drug Delivery, Clin Cardiol; 22 (supp 1): 16-19 (1999).
Laham, R.,Subxyphoid Access of the Normal pericardium: A Novel Drug Delivery Technique, Cath&Cardiovasc Inter 47: 109-111 (1999).
Sonobe, T.,Development of Intracoronary
Brooks Gregory F.
Donovan Stephen
Allergan Inc.
Baran Robert J.
Donovan Stephen
Smith Lynette R. F.
Tongue Lakia J.
LandOfFree
Botulinum neurotoxin eluting stent does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Botulinum neurotoxin eluting stent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Botulinum neurotoxin eluting stent will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3620758